Hua Gong, M.D., Ph.D., is the Chief Operating Officer and Head of Clinical Development and Precision Medicine at Adagene. She has more than 20 years of experience in drug discovery and development, particularly in personalized medicine. Dr. Gong joined Adagene from Novartis Navigate Biopharma where she served as Senior Director, Head of Genomics Biomarker Department. She directly contributed to the U.S. Food and Drug Administration approvals of seven oncology drugs since 2013: Tabrecta™ (capmatinib), Piqray® (alpelisib), Tafinlar® (dabrafenib) + Mekinist® (trametinib) for NSCLC, Kisqali® (ribociclib) , Kymriah® (tisagenlecleucel) and Zykadia® (ceritinib).
Prior to Novartis, she was Executive Director of IVD & CDx at Premier Research Group, where she effectively enabled oncology development programs of their pharmaceutical partners by providing precision medicine solutions. At Prometheus Therapeutics & Diagnostics, Dr. Gong was Associate Director of the Clinical Development Department, where she was responsible for overseeing multiple clinical studies. She successfully contributed to the expansion of Proleukin clinical applications. Additionally, Dr. Gong worked at Pfizer for over 10 years in a variety of positions of increasing responsibility. In her last position at Pfizer, Dr. Gong managed a multi-disciplinary team including in-vitro/vivo biology, PDM, drug safety and biomarker research groups. She was a key contributor to two drugs that entered clinical development.
Dr. Gong received her medical training from An Hui Medical University, her M.S. from Sun Yat-Sen University of Medical Sciences and her Ph.D. in cancer biology from Wayne State University.